Preliminary results for the year ended 31 december 2023

19 april 2024 biodexa pharmaceuticals plc (“biodexa” or the “company” or, together with its subsidiaries, the “group”) preliminary results for the year ended 31 december 2023 biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its audited preliminary results for the year ended 31 december 2023. for more information, please contact: biodexa pharmaceuticals plc stephen stamp, ceo, cfo tel: +44 (0)29 2048 0180 www.biodexapharma.com about biodexa pharmaceuticals plc biodexa pharmaceuticals plc (listed on nasdaq: bdrx) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs.
BDRX Ratings Summary
BDRX Quant Ranking